Lycia Therapeutics, Inc. (LYCA) insider trading
Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 4, 2026.
- Filings shown
- 12
- Open-market buys
- 12
- Open-market sells
- 0
- Buys, 10b5-1 box not checked
- 12 of 12
Counts cover the 12 most recent Form 4 filings Tradune holds for LYCA (filed Oct 26 – Nov 4, 2026). SEC EDGAR Form 4 filings for LYCA last checked Nov 21, 2026, 09:00 UTC; the latest LYCA filing Tradune holds was filed Nov 4, 2026. This is not guaranteed to be the complete record — see LYCA's full Form 4 filing history on SEC EDGAR.
Open-market activity, last 90 days
Purchases (Form 4 code P) and sales (code S) on the 12 filings Tradune holds for LYCA filed Oct 26 – Nov 4, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.
| Insider | Buys | Sells | Shares bought | Shares sold | Value |
|---|---|---|---|---|---|
| Venrock Healthcare Capital Partners III, L.P.10% owner | 12 | 0 | 2,078,749 | — | +$38,522,394 |
Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.
Insider-activity score
39/ 100
Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →
Get alerted when insiders buy the stocks you own
Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.
Free for everyone right now · no card · nothing to buy
How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).
Insider Buying at LYCA
Insiders reported 12 open-market purchases of LYCA in the trailing 90 days, across 1 distinct buyer. The most recent purchase was reported by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Recent Form 4 filings
Source: SEC EDGAR Form 4 · transaction codes explained
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market purchase 10b5-1 box not checked | 8,305 | $26.95 | 6,858,542 (indirect) | +0.1% | Nov 2, 2026 |
† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.
“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market purchase 10b5-1 box not checked | 200 | $26.86 | 6,850,237 (indirect) | +0.0% | Oct 30, 2026 |
| Open-market purchase 10b5-1 box not checked | 8,804 | $26.27 | 6,850,037 (indirect) | +0.1% | Oct 30, 2026 |
| Open-market purchase 10b5-1 box not checked | 1,000 | $26.33 | 6,841,233 (indirect) | +0.0% | Oct 29, 2026 |
| Open-market purchase 10b5-1 box not checked | 4,430 | $25.97 | 6,840,233 (indirect) | +0.1% | Oct 28, 2026 |
| Open-market purchase 10b5-1 box not checked | 10,570 | $25.23 | 6,835,803 (indirect) | +0.2% | Oct 28, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Conversion of derivative Series A Preferred Stock | 25,390,410 | — | — | — | Oct 26, 2026 |
| Conversion of derivative Series B Preferred Stock | 6,284,597 | — | — | — | Oct 26, 2026 |
| Conversion of derivative | 5,631,425 | — | 5,631,425 (indirect) | — | Oct 26, 2026 |
| Conversion of derivative | 1,393,882 | — | 1,393,882 (indirect) | — | Oct 26, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Open-market purchase 10b5-1 box not checked | 8,729 | $25.84 | 6,794,166 (indirect) | +0.1% | Oct 27, 2026 |
| Open-market purchase 10b5-1 box not checked | 31,067 | $26.84 | 6,825,233 (indirect) | +0.5% | Oct 27, 2026 |
| Open-market purchase 10b5-1 box not checked | 8,261 | $26.97 | 6,785,437 (indirect) | +0.1% | Oct 26, 2026 |
| Conversion of derivative Series C Preferred Stock | 17,142,578 | — | — | — | Oct 26, 2026 |
| Conversion of derivative Series D Preferred Stock | 4,408,091 | — | — | — | Oct 26, 2026 |
| Open-market purchase 10b5-1 box not checked | 1,944,444 | $18.00 | 6,777,176 (indirect) | +40% | Oct 26, 2026 |
| Conversion of derivative | 4,779,793 | — | 4,832,732 (indirect) | +9,029% | Oct 26, 2026 |
| Open-market purchase 10b5-1 box not checked | 24,560 | $25.68 | 24,560 (indirect) | — | Oct 23, 2026 |
| Open-market purchase 10b5-1 box not checked | 28,379 | $26.11 | 52,939 (indirect) | +116% | Oct 23, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 20,000 | — | — | — | Oct 22, 2026 |
| Grant / award Stock Option (Right to Buy) | 57,666 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 20,000 | — | — | — | Oct 22, 2026 |
| Grant / award Stock Option (Right to Buy) | 13,307 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 20,000 | — | — | — | Oct 22, 2026 |
| Grant / award Stock Option (Right to Buy) | 24,840 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 68,755 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 110,896 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 399,746 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 73,191 | — | — | — | Aug 11, 2026 |
| Transaction | Shares | Price | Held after | Change† | Date |
|---|---|---|---|---|---|
| Grant / award Stock Option (Right to Buy) | 443,586 | — | — | — | Aug 11, 2026 |
Insider filings reported around the same time
Other companies whose most recent Form 4 was filed closest to LYCA's (Nov 4, 2026).
Frequently asked about LYCA insider activity
How many insiders bought LYCA stock in the last 90 days?
1 distinct insider at Lycia Therapeutics, Inc. reported 12 open-market purchases (Form 4 code P) of LYCA shares in the trailing 90 days, the most recent filed by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.
Who filed the most recent Form 4 for LYCA?
The most recent Form 4 on this page was filed by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 4, 2026, reporting 1 transaction. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.
What was the largest open-market LYCA insider purchase shown?
The largest open-market purchase among the filings shown was 1,944,444 LYCA shares at $18.00 (about $34,999,992) by Venrock Healthcare Capital Partners III, L.P. (10% owner) on Oct 26, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.
Do the recent LYCA insider purchases have the Form 4 10b5-1 box checked?
No. All 12 LYCA open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Venrock Healthcare Capital Partners III, L.P. (10% owner) on Nov 2, 2026, 8,305 shares.
New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.
Get insider alerts for LYCA — and your whole portfolio
Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy
This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.
Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.